Totient - Part of Absci

📍 Cambridge, United States🗓 Founded 2017👥 4 employees💰 Last funded 2018
Biotechnology Research🌐 totient.bio
Website LinkedIn
Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses. Beginning with a population of over 50,000 samples, we have reconstructed antibodies against known and novel extracellular oncology targets: GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, GPR83, and others undisclosed.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Totient - Part of Absci?
Totient - Part of Absci has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Totient - Part of Absci last raise funding?
The most recent investment in Totient - Part of Absci recorded on gritt.io was in 2018.
When was Totient - Part of Absci founded?
Totient - Part of Absci was founded in 2017.
What industry is Totient - Part of Absci in?
Totient - Part of Absci operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Totient - Part of Absci based?
Totient - Part of Absci is headquartered in Cambridge, United States.